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Abstract 
Background: Malaria is one of the most prevalent parasitic diseases in the world and represents a threat to travellers 
visiting endemic areas. Chemoprophylaxis is the prevention measure used in travel medicine, avoiding clinical mani-
festations and protecting against the development of severe disease and death.
Methods: Retrospective and descriptive analysis of malaria prevention data in travellers was recorded from a travel 
medicine clinic in São Paulo, Brazil, between January 2006 and December 2010. All the medical records of travellers, 
who had travelled to areas with risk of disease transmission, including Brazil, were analysed. Demographic characteris-
tics of travellers, travel details and recommendations for preventing malaria were also seen.
Results: During the study period, 2836 pre-travel consultations were carried out on 2744 individuals (92 were con-
sulted twice). The most common reasons for travelling were tourism and work. The most common destinations were 
Africa (24.5%), Europe (21.2%), Asia (16.6%) and locations within Brazil (14.9%). In general prophylaxis against malaria 
was recommended in 10.3% of all the consultations. African destinations vs Asian, Brazilian and other destinations and 
length of stay ≤30 days were independently associated with the higher odds of chemoprophylaxis recommendation 
after the logistic regression.
Conclusion: The prophylaxis against malaria was recommended in 10.3% of the consultations. The authors believe 
that a coherent measure of malaria prevention in Brazil and for international travellers would be to recommend for all 
parts of the North Brazil, avoidance of mosquito bites and immediate consultation of a physician in case of fever dur-
ing or after the journey is recommended.
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Background
Malaria is a preventable, diagnosable and treatable dis-
ease. With innovation and roll out of interventions 
there are fewer people dying from malaria now that in 
any other historical period. During 2015, there were an 
estimated 214 million cases of malaria and an estimated 
438,000 deaths (range 236,000–635,000) globally [1].
The burden of malaria among residents in Latin Amer-
ica has been declining in recent years. The number of 
confirmed malaria cases in the region decreased from 
1.2 million in 2000 to 427,000 cases in 2013. Reductions 
of  >75% in the incidence of microscopically-confirmed 
malaria cases were reported in 13 out of 21 countries. 
Brazil and Colombia are on track to achieve a 75% 
decrease in case incidence by 2015, which would pre-
dominantly concern Plasmodium vivax malaria trans-
mission [1]. Brazilian Amazon concentrates 99.8% of 
malaria cases in the country, a scenario in which the P. 
vivax (84%) is the prevalent species. Currently, the states 
of Acre, Amazonas, Pará, Amapá, Roraima and Rondônia 
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present the greatest risks of transmission of Plasmodium 
falciparum, according to National Malaria Control Pro-
gramme (PNCM) data from the Brazilian Ministry of 
Health [2].
The malaria in the North of Brazil is dynamic and with 
heterogeneous occurrence, therefore, the risk of malaria 
transmission in the Brazilian Amazon is not homoge-
neous (Fig.  1). Urban malaria is limited to a few cities, 
especially in their suburbs which usually are not visited 
by tourists. Additionally, malaria in this region is often 
observed in gold mining areas and surrounding settle-
ments, posing high risk to domestic travelers, which go 
to the areas looking for new job opportunities. For many 
years there has been no transmission of malaria in the 
most sought after tourist destinations such as Belém, 
Santarém, Alter do Chão, cities of the State of Pará.
Approximately 125 million international travellers per 
year will visit areas where there is a risk of malaria trans-
mission, 10,000–30,000 of them will fall sick with malaria 
and between 1 and 4% of travellers who acquire falcipa-
rum malaria will die [3].
As there is no vaccine against malaria, prevention 
of disease consists of the person protective measures 
against mosquito bites and chemoprophylaxis. Chemo-
prophylaxis remains one of the main therapeutic inter-
vention to prevent malaria-related severity and mortality 
[4, 5]. Malaria chemoprophylaxis has to be taken regu-
larly to be effective and previous studies have shown poor 
compliance to be a common problem [6–9], with a con-
siderable variation in efficacy comparing areas with dif-
ferent transmission risks [9]. Because travellers may be 
persuaded to stop taking medication by peer pressure, 
not seeing mosquitoes, and adverse reactions to medi-
cations, clinicians should be prepared to address these 
barriers [10]. Especially for long-term travellers, malaria 
prevention is a complex issue and requires expert and 
individualized advice from travel medicine specialists 
[11]. In the malaria elimination era, knowledge and prac-
tices regarding malaria chemoprophylaxis among health 
professional and travellers in malaria endemic areas is 
also important for preventing reintroduction of malaria 
to malaria-free zones [12].
Decisions on malaria chemoprophylaxis are compli-
cated by a lack of standardized recommendations, con-
troversies, and misconceptions [13]. Because of recent 
declining malaria transmission in Latin America, some 
researchers and authorities have not recommended chem-
oprophylaxis for most travellers to this region [14, 15]. In 
Brazil, malaria prevention among travellers is an issue that 
leads to discussions and controversies between malariolo-
gists and policy-makers. Mostly, chemoprophylaxis rec-
ommendation is reserved for specific situations in which 
the risk of becoming ill of severe P. falciparum malaria is 
greater than the risk of severe adverse events related to 
the use of chemoprophylatic drugs. Furthermore, there is 
a concern by the authorities that an amplified chemopro-
phylaxis could contribute to the emergence of resistance 
to anti-malarial treatments used in Brazil [15]. There are 
a range of suitable options for chemoprophylaxis in Latin 
America, including atovaquone-proguanil, doxycycline, 
mefloquine, and, in selected areas, chloroquine [16]. Cur-
rently, doxycycline and chloroquine are the drug regimens 
available for chemoprophylaxis in Brazil [15].
The aim of this study was to describe the pre-travel 
recommendation of malaria chemoprophylaxis in a free 
public clinic travel medicine in the city of São Paulo, Bra-
zil. The results presented in this study do not represent 
the overall Brazilian travelling population.
Methods
Participants and procedures
This was a retrospective, descriptive study of the pre-
travel counselling provided between January 2006 and 
December 2010 at the Travel Medicine Clinic of the Insti-
tuto de Infectologia Emílio Ribas, located in the city of 
São Paulo, Brazil [17]. All the medical records of individ-
uals who sought pre-travel health advice during the study 
period were analysed. Data related to the socio-demo-
graphic characteristics (gender, age, schooling), clini-
cal data (presence of any immunosuppressive condition, 
HIV infection, diabetes mellitus and depression), ways 
by which travellers became aware of the travel medicine 
services, travel characteristics (reason of the travel, desti-
nations, accommodation type, travel length) and malaria 
chemoprophylaxis prescription (yes/no and prescribed 
drug) were retrieved.
Statistical analysis
Only variables presenting completeness higher than 80% 
were analysed. Data were analysed using SPSS version 
21.0 for Windows (SPSS Inc. Chicago, IL, USA). Propor-
tions of individuals for which they were recommended 
No transmission = sem transmissão
Low risk = baixo risco
Medium risk = médio risco
High risk = alto risco
Fig. 1 Areas at risk of malária transmission in Brazil
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chemoprophylaxis were compared by Chi square test (cor-
rected by Fisher’ test if necessary); differences were consid-
ered statistically significant for p  <  0.05. The crude Odds 
Ratio (OR) with its respective 95% Confidence Interval (95% 
CI) was determined considering chemoprophylaxis recom-
mendation as the dependent variables. Logistic regression 
was used for the multivariable analyses and the adjusted 
ORs (AOR) with 95% CI were also calculated. All vari-
ables associated with the outcomes at a significance level of 
p < 0.20 in the univariable analysis were included in the mul-
tivariable analysis. Statistical significance was considered if 
p < 0.05 in the Hosmer–Lemeshow goodness-of-fit test.
Ethical clearance
The study was approved by the Ethics in Medical 
Research Committee of the Instituto de Infectologia 
Emílio Ribas (09/12) and by the Research Ethics Com-
mittee of the Hospital das Clínicas, School of Medicine, 
University of São Paulo (311/12), also located in the city 
of São Paulo, Brazil.
Results
Population characteristics
Among the 2744 travellers who sought travel medicine 
consultations between January 2006 and December 
2010, there were 2836 pre-travel consultations, since 92 
of those travellers were attended more than once in the 
study period. Regarding gender, 51.1% of the attended 
population were female. Most of the travellers (54.2%) 
were aged between 18 and 34 years old, with a mean age 
of 34.7 years and a median of 31.3 years. A total of 75.6% 
had  >11  years of schooling. In relation to clinical vari-
ables, any immunosuppressive condition was reported 
in 2.4%, HIV infection in 1.2%, diabetes mellitus in 1.3% 
and depression in 3.3% of the study population (Table 1). 
When travellers were asked how they had become 
aware of the travel medicine service, the most common 
responses were from the suggestion of friends, health 
professionals and electronic media.
Travel characteristics
Among the reasons for travelling, study or work (52.7%) 
and tourism (36.1%) prevailed. The most common destina-
tions were Africa (24.5%), Europe (21.2%), locations within 
Brazil (15.1%) and Asia (14.1%). Most of the individu-
als travelling within Brazil had as destinations the North 
(51.4%) or Central-West (15.9%) regions of the country. 
Hotels and hostels (rented or provided by an employer) 
were the most commonly reported types of accommo-
dations (34.9%). For 1217 (46.0%) of the consultations, 
travellers estimated that the length of their stay would 
be  ≤30  days (Table  2). Of the 2836 consultations, 901 
(31.8%) were conducted within 7–21 days before the travel.
Malaria prevention recommendations
Prophylaxis against malaria was recommended in 
292 of the 2836 consultations (10.3%). The most pre-
scribed chemoprophylaxis regimens were doxycyline 
(210/71.9%), atovaquone-proguanil (49/16.8%), meflo-
quine (27/9.2%) and chloroquine (6/2.1%). Stand-by 
emergency treatments for malaria were recommended 
for 34 of the orientations (1.2%). All travellers were 
advised on personal measures against mosquito bites.
Factors associated to malaria chemoprophylaxis 
recommendation
Table 3 summarizes the results of the univariable analy-
sis evaluating factors associated with chemoprophy-
laxis recommendation. Male gender [OR 1.37 (95% CI 
1.07–1.75)]; age < median [OR 1.34 (95% CI 1.05–1.71)]; 
Table 1 Socio-demographic and  clinical characteristics 
of  the population assisted at  the Instituto Emílio Ribas 
travel clinics, São Paulo, Brazil, between  January 2006 
and December 2010
Variable (completeness) N %
Gender (100%)
Male 1343 48.9
Female 1401 51.1
Age (years; 100%)
0–9 66 2.4
10–17 90 3.3
18–24 522 19.0
25–34 966 35.2
35–44 486 17.7
45–59 457 16.7
≥60 157 5.7
Mean (standard deviation) 34.7 (±14.0) –
Median (interquartile range) 31.3 (0.1–91.5) –
Schooling (years; 90.3%)
≥12 1872 75.6
8–11 472 19.0
<8 133 5.4
Immunosuppressive condition (100%)
No 2678 97.6
Yes 66 2.4
HIV infection (100%)
No 2711 98.8
Yes 33 1.2
Diabetes mellitus (100%)
No 2708 98.7
Yes 36 1.3
Depression (100%)
No 2653 96.7
Yes 91 3.3
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African destinations vs Asian [OR 4.62 (95% CI 3.07–
6.95)]; Brazilian [OR 4.67 (95% CI 3.11–7.04)]; and other 
destinations [OR 9.12 (95% CI 6.53–12.74); and length 
of travel stay  ≤30  days [OR 3.33 (95% CI 2.17–5.11)]; 
were associated with the higher odds of chemoprophy-
laxis recommendation. Schooling ≥12 years (vs <8 years) 
[OR 0.47 (95% CI 0.23–0.98)]; and tourism travels 
(vs work travels) [OR 0.72 (95% CI 0.56–0.94)]; were 
associated with the lower odds of chemoprophylaxis 
recommendation.
African destinations vs Asian [AOR 5.01 (95% CI 3.23–
7.14); Brazilian [AOR 4.76 (95% CI 3.13–7.14)]; and other 
destinations [AOR 8.33 (95% CI 5.88–12.50)]; and length 
of travel stay ≤30  days [AOR 2.63 (95% CI 1.67–4.00)]; 
were independently associated with the higher odds of 
chemoprophylaxis recommendation after the logistic 
regression (Table 4).
Discussion
Currently, available malaria transmission indicators are 
important tools for the assessment and understand-
ing of the risks of disease transmission in populations of 
endemic regions. However, these values among individu-
als moving from non-endemic areas for malaria transmis-
sion areas are little known [15]. Non-immune migrants, 
mobile populations and travellers population groups are 
at considerably higher risk of contracting malaria, and 
Table 2 Characteristics of  the travel population assisted 
at  the Instituto Emílio Ribas travel clinics, São Paulo, Bra-
zil, between January 2006 and December 2010
Variable (completeness) N %
Travel reason (99.0%)
Study or work 1480 52.7
Tourism 1013 36.1
Multiple or others 316 11.2
Travel destination (98.8%)
Africa 694 24.7
Asia 417 14.9
Brazil 422 15.1
Others 1270 45.3
Accommodation type (86.2%)
Hotel or hostel 854 34.9
Others 1590 65.1
Length of stay (in days) (93.3%)
≤30 1217 46.0
31–180 805 30.4
>180 624 23.6
Table 3 Univariable analysis to  identify factors associ-
ated to  malaria chemoprophylaxis recommendation 
among  individuals attended at  the Instituto de Infectolo-
gia Emílio Ribas, in  São Paulo, Brazil, from  January 2006 
to December 2010
CI confidence interval
Variables Chemoprophylaxis 
recommendation
OR (CI 95%)
Yes (n;  %) No (n;  %)
Gender
Male 163 (55.8) 1220 (48.0) 1
Female 129 (44.2) 1324 (52.0) 1.37 (1.07–1.75)
Age group
<Median 165 (56.5) 1253 (49.3) 1
≥Median 127 (43.5) 1291 (50.7) 1.34 (1.05–1.71)
Schooling (years; 90.3%)
<8 8 (2.9) 128 (5.6) 1
8–11 40 (14.7) 447 (19.6) 0.70 (0.32–1.53)
≥12 225 (82.4) 1706 (74.8) 0.47 (0.23–0.98)
Any immunosupressive condition
No 286 (97.9) 2483 (97.6) 1 
Yes 6 (2.1) 61 (2.4) 1.17 (0.50–2.73)
HIV infection
No 290 (99.3) 2512 (98.7) 1 
Yes 2 (0.7) 32 (1.3) 1.85 (0.44–7.75)
Diabetes mellitus
No 288 (98.6) 2510 (98.7) 1 
Yes 4 (1.4) 34 (1.3) 0.97 (0.34–2.77)
Depression
No 283 (96.9) 2459 (96.7) 1 
Yes 9 (3.1) 85 (3.3) 1.87 (0.54–2.18)
Travel reason
Study or work 137 (47.2) 1343 (53.3) 1 
Tourism 125 (43.1) 888 (35.3) 0.72 (0.56–0.94)
Multiples or others 28 (9.7) 288 (11.4) 1.05 (0.68–1.61)
Travel destination
Africa 183 (62.9) 511 (20.3) 1 
Asia 30 (10.3) 387 (15.5) 4.62 (3.07–6.95)
Brazil 30 (10.3) 392 (15.6) 4.67 (3.11–7.04)
Latin American endemic 
countries
11 (3.8) 205 (8.2) 6.67 (3.55–12.53)
Others 37 (12.7) 1017 (40.5) 9.84 (6.81–14.23)
Accomodation type 2512
Hotel or hostel 79 (32.8) 775 (35.2) 1 
Others 162 (67.2) 1428 (64.8) 0.90 (0.68–1.19)
Length of stay (in days)
≤30 154 (54.2) 1063 (45.0) 1 
31–180 104 (36.6) 701 (29.7) 0.98 (0.75–1.27)
>180 26 (9.2) 598 (25.3) 3.33 (2.17–5.11)
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developing severe disease, than populations living in 
endemic areas [1, 3]. Furthermore, stronger malaria sur-
veillance and prevention systems are urgently needed to 
enable a timely and effective malaria response in elimi-
nating areas for preventing reintroduction. The policy 
of prevention of malaria recommended by the World 
Health Organization is to recognize differencial risks 
of transmission, personal measures avoiding mosquito 
bites, early diagnosis and treatment, chemoprophylaxis 
and/or self-administered treatment when indicated [3].
In this work, most of the travellers were adults with 
high educational level travelling by work or study rea-
sons. When travellers were asked how they had become 
aware of the travel medicine service, the most common 
responses were from suggestions of friends, health pro-
fessionals and electronic media. Agricultural and mining 
projects attract many temporary workers to the Brazilian 
Amazon, which may return to their places of origin car-
rying malaria [18]. Destinations of the study population 
to Africa and locations within North or Central-West 
Brazilian regions were common.
Most of the cases diagnosed and reported outside the 
Brazilian Amazon corresponded to imported cases origi-
nating from the Amazon or other Central and South 
American, African or Asian countries that have active 
transmission [19]. Interestingly, previous studies per-
formed in areas where malaria transmission does not 
occur, showed P. vivax relapses rates ranging from 25% 
over 7 years in São Paulo [20] to 40% over 6 years in Rio 
de Janeiro [21] in individuals returning from endemic 
areas. A delay in diagnosis and treatment, common in 
areas where the disease is not endemic, can result in seri-
ous illness and death, also proportionately more common 
in non-Amazon region [22]. Probably, the bigger number 
of people with African destinations searching for medical 
travel services is influenced by the massive report by 
the Brazilian press of deaths in patients with falciparum 
malaria returning from Africa to non-endemic regions of 
the country [23, 24].
Prophylaxis against malaria was recommended in 
10.3% of the consultations. Consistently, in another Bra-
zilian study, authors reported that such prophylaxis was 
recommended for 9.1% of the travellers evaluated in their 
study [25], suggesting that vast majority of the travellers 
do not present a considerable risk of acquiring malaria in 
their destinations according the medical evaluation. The 
decision to use chemoprophylaxis on travellers depends 
on the individual’s risk–benefit analysis, weighing the risk 
of contracting malaria against the possible adverse effects 
of anti-malarial medications, underlying health condi-
tions, duration of travel, adherence, cost and finally the 
licensed status of the anti-malarial medications [15, 26, 
27]. Brazilian official guidelines also include the risk of 
P. falciparum malaria as a major issue in the decision of 
recommending the use of chemoprophylaxis [15].
In this study sample, the prophylactic drug most 
often prescribed was doxycycline (71.9%), followed by 
atovaquone-proguanil (16.8%). In the study conducted by 
Wilder-Smith et al., doxycycline was also found to be the 
most widely prescribed anti-malarial drug [28]. Accord-
ing the Brazilian guideline, there is no consensus about 
the best chemoprophylactic regimen to be used in each 
particular case [15]. Doxycycline was suggested as a good 
chemoprophylaxis for short-term travellers at particu-
lar risk of chloroquine/proguanil resistant P. falciparum 
malaria [29]. However, chemoprophylaxis failures have 
been related to a lack of compliance with doxycycline 
due to its short elimination half-life [30]. Atovaquone-
proguanil is at least as efficient as mefloquine [9]. Meflo-
quine was suggested as the elective chemoprophylaxis 
for long-term travellers at particular risk of chloroquine-
resistant P. falciparum malaria [31]. Regarding safety, a 
systematic review of randomized and quasi-randomized 
controlled trials showed that atovaquone-proguanil and 
doxycycline are the best tolerated regimens, and meflo-
quine is associated with adverse neuropsychiatric out-
comes [32]. As mefloquine and atovaquone-proguanil are 
not available for purchase nor is part of National Malaria 
Control Programme in Brazilian territory, their use by 
travellers was highly limited.
Travel to African destinations was the most impor-
tant factor associated to malaria chemoprophylaxis rec-
ommendation. Again, this finding may be explained by 
the recommendation from Brazilian guidelines to use 
chemoprophylaxis by travellers visiting P. falciparum 
endemic areas [15]. On the other hand, the large contri-
bution of P. vivax infections in Asia and Latin America, 
including the Brazilian Amazon [33], explains the low 
Table 4 Variables independently associated with  the rec-
ommendation of  malaria chemoprophylaxis in  pre-travel 
consultations among individuals attended at the Instituto 
de Infectologia Emílio Ribas, in São Paulo, Brazil, from Jan-
uary 2006 to December 2010
AOR adjusted odds ratio, CI confidence interval
Variable AOR 95% CI
Destination
Africa 1 –
Asia 5.01 3.23–7.14
Brazil 4.76 3.13–7.14
Latin American endemic countries 6.14 4.23–8.50
Other 8.33 5.88–12.50
Length of stay (days)
≤30 1 –
>180 2.63 1.67–4.00
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chemoprophylaxis prescription to travellers visiting these 
areas. Today, P. vivax accounts for 84% of registered cases 
of malaria in Brazil [2]. Previous studies had already 
demonstrated a tendency in the reduction of the recom-
mendation of chemoprophylaxis for travellers with des-
tinations to the Indian Subcontinent and Latin America 
where P. vivax predominates [14, 34]. However, P. vivax 
causes relapses [35, 36] and potential severity [35, 36], 
changing the old paradigm of not considering prophy-
laxis in those areas [16]. Regarding the chemoprophy-
laxis for vivax malaria, the Brazilian policy is not to make 
this recommendation [15], due to all the complexities 
involved for its practice. Chemoprophylaxis for P. vivax 
requires essential measures such as G6PD status assess-
ment, not always practical in travel medicine services.
It was expected in this work that pre-travel preparation 
of travellers with immune suppression due to any medical 
condition would be a greater concern regarding malaria 
chemoprophylaxis. Immunocompromised travellers to 
malaria-endemic areas should be prescribed malaria 
chemoprophylaxis and receive counseling about mosquito 
bite avoidance [37]. Special concerns for immunocompro-
mised travellers include any of the following possibilities 
[37]: (a) drugs used for malaria chemoprophylaxis may 
interact with drugs in the traveller’s maintenance regimen; 
(b) the underlying medical condition or immunosuppres-
sive regimen may predispose the immunocompromised 
traveller to more serious disease from malaria infection; 
(c) malaria infection and the drugs used to treat malaria 
infection may exacerbate the underlying disease; and (d) 
the severity of malaria is increased in HIV-infected people.
Recommendations for malaria chemoprophylaxis 
involve complex decision-making and must consider the 
destination, the host, the activities, and the duration of 
exposure. The choice of medication depends on the risk 
of malaria at the destination, resistance, the profile of the 
traveller (contra-indications, underlying health condi-
tions, purpose of travel such as travellers visiting friends 
and relatives (VFR), the duration of travel and finally cost 
and adherence issues. The registration status of the anti-
malarial medications is another factor.
Malaria treatment policy in Brazil is guaranteed by the 
government. Therefore, anti-malarial drugs are distrib-
uted free of charge only by reference public services in 
the country. An ideal anti-malarial for malaria prevention 
is the one of lower cost, with less risk of causing adverse 
events, with easy access and easy dosage schedule.
The association atovaquone and proguanil could be 
the ideal choice for travellers but because of its high 
cost, its inclusion in the therapeutic arsenal of Brazil is 
questionable.
A coherent measure of malaria prevention in Brazil 
and for international travellers would be to recommend 
for all parts of Northern Brazil, avoidance of mosquito 
bites and immediate consultation of a physician in case of 
fever during or after the journey is recommended. Obvi-
ously, the accurate evaluation of the risk of the traveller 
in acquiring malaria in the Brazilian Amazon, chemopro-
phylaxis may be indicated.
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